Treatment with MK-2206 resulted in decreased viable cell recovery for all ATMKO thymic T-LBLs without significantly inhibiting viability of NF-kB-dependent ATMKO B cell lymphomas [34] (Fig 5A and S1 Appendix, p<0.001). The gene discussed is NFKB1; the disease is B-cell non-Hodgkin lymphoma.